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INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with a range of symptoms, comorbidities and reduced health related quality of life. [1 -3] Based on patients' and physicians' perspectives as well as recent research developments, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) together with the Outcome Measures in Rheumatology (OMERACT) international consensus effort developed an updated core outcome set (COS) for PsA [4] , describing the outcomes (domains) that should be measured and reported in all randomized controlled trials. The updated PsA COS was endorsed in May 2016 by OMERACT and includes the following mandatory ('inner core') domains:
Musculoskeletal (MSK) disease activity, Skin disease activity, Pain, Patient global, Physical function, Health
Related Quality of Life (HRQoL), Fatigue and Systemic inflammation. Four other domains (Participation, Economic cost, Structural damage and Emotional well-being) were considered important but not mandatory (middle COS circle), and four domains (Sleep, Independence, Stiffness and Treatment burden)
were placed in the "research agenda" (outer COS circle). [5] The OMERACT Filter 2.0 provides guidelines for developing a core outcome measurement set (COMS) which comprises the appropriate instruments to assess each COS domain. [6] Great heterogeneity exists in instruments used for measuring the core domains of PsA, and several have been "borrowed" from other diseases without confirming their measurement properties in PsA. [7] Instruments should have evidence of validity, reliability and responsiveness as described in detail by the COnsensus based standards for the Selection of health Measurement INstruments organisation (COSMIN). [8] In addition, an instrument needs to be feasible and yield interpretable results. [9] These qualities are summarized by the original OMERACT Filter as 'Truth, Discrimination and Feasibility'. [10] As highlighted by the OMERACT Filter 2.0, the COS development was not influenced by considering how to measure the domains; neither the type of assessment nor the availability of specific instruments was taken into account. Development of the PsA COMS therefore implies that subsequently all available instruments per COS domain are identified, evaluated and judged for overall applicability. To support this GRAPPA-OMERACT initiative, the objective of this systematic literature review was to synthesise the evidence for good measurement properties of patient reported outcomes measures (PROMS) in PsA and align instruments and COS domains.
METHODS
A protocol was uploaded to PROSPERO prior to initiation of the systematic review (PROSPERO: CRD42016032546). The review adheres to the COSMIN guidelines [11 - 
13] and the Preferred Reporting
Items for Systematic reviews and Meta-Analyses (PRISMA-statement). [14] Literature search
A research librarian (EMB) and the first-author (PH) performed a systematic search in MEDLINE via
PubMed from 1966, EMBASE via OVID from 1974, and PsycINFO via OVID from 1806, all to 1 January 2017.
The search was designed to identify all types of outcome measurement instruments in PsA. The search was limited to humans and consisted of two overall terms: (1) Target population: MeSH subheadings and free text words in title/abstract (ti/ab) were combined by the Boolean operator 'OR' to search for the target population (PsA) in the databases; (2) Measurement properties: Search filters have been developed to improve the search of studies on measurement properties in MEDLINE and EMBASE. [15] We used the highly sensitive filter validated for MEDLINE (sensitivity of 97.4%) and the filter for EMBASE optimized for this search. In PsycINFO only the target population was searched. The full search strategy is available in supplementary Table A .
Eligibility criteria
Per protocol, studies were considered eligible if published as full text articles in the English language with an aim of developing or assessing measurement properties of outcome measurements in PsA patients.
However, for feasibility reasons and to ensure applicability of the COSMIN guidelines, it was subsequently decided to evaluate only patient reported instruments in this review, and allocate the assessment of the remaining instruments to parallel work streams. The stepwise eligibility and inclusion process is depicted in Figure 1 . Studies evaluating instruments used solely for screening or diagnostic purposes were not eligible. Only studies including ≥50% patients with PsA or reporting PsA subgroup results separately were included.
Selection of articles
PH eliminated duplicates and the remaining references were assessed for eligibility by two independent reviewers (PH, KH). Titles, abstracts and full-text articles (when appropriate) were reviewed and selection was performed by consensus with involvement of co-authors (RC, LK, EMB, A-MO) if needed. Additional studies identified by co-authors or reviews were considered for inclusion. Search results were handled by Reference Manager 12 (Thomson Reuters, USA).
Extraction of study characteristics and description of PROM characteristics
PH and KH independently extracted data on the characteristics of the studies (number, age and gender of participants, study setting and language). Characteristics of the PROMs (e.g., items, scoring, feasibility and availability) were obtained by PH from the questionnaires, background literature, user manuals or European League Against Rheumatism (EULAR) Outcome Measures Library [16] or by contacting authors/copyright holders.
Mapping the PROMs to corresponding COS domains
The working group, including Patient Research Partners (PRPs) (NG, MdW) reviewed the PROMs to achieve consensus on how to present them by COS domains. Separate scales within a multi-scale instrument as well as summed scale scores were perceived as unique instruments and mapped by their corresponding COS domains. Measurements of HRQoL were categorized as either health status surveys or health value/preference/utility assessments. The latter were reported within the COS domain 'economic cost'.
Extraction and evaluation of the methodological study quality per measurement property per instrument
The COSMIN checklist enables a critical evaluation of the methodological quality of studies investigating measurement properties [11] . A four-point system is provided to score the methodological quality of a study per measurement property as 'excellent', 'good', 'fair' or 'poor'. [13] Four independent reviewers worked in teams of two (PH/LK, PH/AMO, PH/YYL) to reach consensus on the COSMIN ratings. A third reviewer (CT or RC) resolved disagreements. Information on score interpretation (mean (SD) of scores, floor and ceiling effects, minimally (clinically) important difference/improvement (M(C)ID/MCII), minimal detectable change (MDC) and Patient Acceptable Symptom State (PASS)) was extracted.
Evaluation of the result of the measurement properties
The results of measurement properties per instrument were evaluated (concurrently with the rating of the study methodology) as positive (+), indeterminate (?) or negative (-) per study in accordance with the quality criteria described by the 'COSMIN & Core Outcome Measures in Effectiveness Trials (COMET) collaboration'. [17] Level of evidence for the quality of the measurement properties of PROMs in PsA
To determine the overall level of evidence for a measurement property of an instrument, data were synthesized by combining the quality of the measurement property results, the methodological study qualities and the consistency of the findings [18, 19] ( Table 1) . Table 1 Level of evidence for the quality of a measurement property
Consistent findings of good measurement property in multiple studies of good methodological quality or in one study of excellent methodological quality. Consistent findings of poor measurement property in multiple studies of good methodological quality or in one study of excellent methodological quality.
Moderate (++)
Moderate (--) Consistent findings of good measurement property in multiple studies of fair methodological quality or in one study of good methodological quality. Consistent findings of poor measurement property in multiple studies of fair methodological quality or in one study of good methodological quality.
Limited (+) Limited (-)
One study of fair methodological quality with findings of good measurement property. One study of fair methodological quality with findings of poor measurement property
Conflicting (±)
Conflicting findings on the measurement property quality results across studies.
Unknown (?)
Only studies of poor methodological quality were identified.
Reporting the results of the evidence synthesis
As described by OMERACT [9] , the COSMIN & COMET collaboration [17] and the Food And Drug Administration (FDA) [20] guidelines, evidence on validity (especially content validity) and reliability should be prerequisites for an instrument to be considered for further evaluation/application. If an instrument
does not measure what it intends to or produces unreliable estimates, it is irrelevant to test for e.g., responsiveness. Thus, in the result section of this systematic review, we have chosen to highlight the 'candidate' instruments per COS domain that have at least limited evidence on reliability and validity and no evidence for any poor measurement properties.
The main evidence synthesis includes all studies of a PROM but conflicting evidence on measurement properties across language versions is described for 'candidate' PROMs. Available values for Cronbach-α, interclass correlation coefficients (ICC) and floor/ceiling effects are described in the text while remaining results on measurement properties and score interpretation can be obtained from the tables.
RESULTS

Study selection
As illustrated in Figure 1 ; from 5844 unique references identified, 334 studies were eligible for further assessment. Of these, 77 reviews were excluded, as were 87 abstracts/conference papers without full-text.
An additional 11 papers were added from experts and reference lists resulting in 181 studies for full-text reading. Eighty of these failed the inclusion criteria due to reasons depicted in Figure 1 . Of the remaining 101 studies, clinician-reported (n=18) and composite (n=28) measures were excluded due to the focus on PROMs only, leaving 55 studies for final inclusion.
Study characteristics
The included studies were published between 1992 and 2016 and were mainly observational cohorts of PsA patients in their 4 th and 5 th decades of life. Most studies were performed in English speaking countries and evaluated more than one PROM ( Table 2 ).
Characteristics of the PROMs
A total of 44 instruments covering 89 separate PROMs were evaluated (supplementary Tables B1, B2 ).
Each PROM was mapped to the corresponding COS domain. The content, scoring and feasibility aspects of each PROM are described in supplementary Table B2 .
Rating of the methodological quality and measurement property results of each study
The methodological quality ratings and ratings of the measurement property results are presented for each PROM in supplementary Level of evidence on the measurement properties for each of the evaluated PROMs Table 3 presents the overall evidence synthesis. Generally, most studies were of poor or fair quality resulting in limited or unknown evidence for the evaluated measurement properties. According to the results of the COSMIN analyses (supplementary Table D) , frequent methodological limitations were small sample sizes, lack of information on handling of missing data, lack of information on unidimensionality when assessing internal consistency, insufficient methods for examining/reporting content validity, inappropriate statistical methods for testing responsiveness, and lack of hypotheses and psychometric information on comparators when testing construct validity.
Evidence for PROMS measuring PsA core domains
MUSCULOSKELETAL DISEASE ACTIVITY.
The core domain of musculoskeletal disease activity is currently measured using a combination of physician assessments (clinical examination) and PROMs, and depending on the purpose of the study also biologic inflammatory markers and/or assessments of PsA pathophysiology using tissue imaging techniques. Six
PROMs that aim to evaluate the concept of patient reported disease activity were retrieved ( Table 3 ). The Stockerau Activity Score for Psoriatic Arthritis (SASPA) in German was currently the best candidate based on limited evidence for unidimensionality, internal consistency (Cronbach-α=0.875) as well as structural validity by factor analysis (supplementary Table C and D) . SASPA is short, free and easy to score (supplementary Table B2 ). The main limitations of SASPA are the unknown content validity and only the
SKIN DISEASE ACTIVITY
Three instruments were found that aim to measure patient reported skin disease activity (Table 3) Table D) .
PAIN
Six PROMs were evaluated (Table 3 ). None of these had evidence on both reliability and validity. The Table D ). The main limitations of SF-36 BP are the unknown evidence for reliability and content validity, and the requirement of software to calculate scores (supplementary Table B2 ). The visual analogue scale (VAS) of pain (1 week recall time) had limited evidence for construct validity (external relationships) (Table 3) , and MID was reported (Table 3, and supplementary Table C and D) .
PATIENT GLOBAL
Eight measures of Patient Global (PtG) were identified and included VAS and numeric rating scales (NRS) with varying recall periods. The phrasing of the PtG item addressed the impact on overall well-being of either 1) arthritis, 2) psoriasis, or 3) PsA (as a whole) as described in supplementary Table B2 . Only the VAS of PtG due to PsA (1 week recall) had evidence of both validity and reliability in PsA including limited evidence for construct validity (external relationships) and moderate evidence for test-retest reliability (ICC (95%CI) =0.87(0.83-0.90)). Values of MID, PASS and MCII were reported across languages and recall versions of VAS PtG (Table 3, supplementary Tables C-E) . The NRS of PtG due to PsA (1 week recall) had moderate evidence for construct validity (external relationships and known group validity) and floor/ceiling effects were reported up to ~ 8 %/3 % (Table 3 and supplementary Table D) .
PHYSICAL FUNCTION
Twenty-three PROMs were evaluated (Table 3) , and three of these had evidence on both reliability and validity including the Bath Ankylosing Functional Index (BASFI), the SF-36 Physical Function subscale (SF-36 PF) and the Health Assessment Questionnaire Disability Index (HAQ-DI). Based on evidence from English and Chinese studies using Rasch analysis and principal component analysis, the SF-36 PF was the best candidate with strong evidence for unidimensionality, internal consistency (Cronbach α=0.91-0.92) and good structural validity. Evidence for construct validity was moderate and limited for internal and external relationships, respectively (Table 3) . Floor and ceiling effects were less than 10% and MID was reported (supplementary Table D ). The HAQ-DI was the most frequently assessed instrument for this domain and had strong evidence for good internal consistency and structural validity (Table 3) . However Rasch analysis suggested better properties for the SF-36 PF in a study that compared the two instruments. [33] HAQ-DI was limited by floor effect (up to 50%) and had conflicting evidence on construct validity across languages (supplementary Tables C-E) .
HEALTH RELATED QUALITY OF LIFE/LIFE IMPACT
Ten PROMs were identified (Table 3) . Of these, the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, the PsA Quality of Life instrument (PsAQoL) and the VITACORA-19 (Spanish and Italian versions) all had some evidence on both reliability and validity. PsAID was translated and evaluated in several languages during the development phase and appeared a good candidate based on strong evidence for content validity and moderate evidence for good test-retest reliability and for good construct validity (external relationships) of the 12-item version (PsAID-12). Similar findings existed for PsAID-9 except that evidence for construct validity was limited. Floor/ceiling effects of PsAID were <1%, and values for PASS were provided (supplementary Table D 
FATIGUE
Four instruments were identified (Table 3) . Evidence for validity and reliability was only available for the Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-Fatigue) including limited evidence for good test-retest reliability (ICC=0.95) and construct validity (external relationships) ( Table 3,   supplementary Table D) .
PROMs measuring domains of the middle circle of the PsA COS
PARTICIPATION
Eleven PROMs were evaluated ( Table 3 ). The three subscales of the Social Role Participation Questionnaire were the only measurements with evidence of both reliability and validity including limited evidence for good test-retest reliability, content validity and construct (external relationships and known group) validity.
The Work Productivity Survey had limited evidence for good construct validity and responsiveness but high floor effects found for certain items (73.7% (item 2) and 77.3% (item 8)) ( Table 3, supplementary Table D) .
The SF-36 role emotional, role physical and social functioning subscales had moderate evidence for good construct validity (hypotheses testing regarding known groups, internal and external relationships).
EMOTIONAL WELL-BEING
Nine instruments were identified from Chinese and English studies but none had evidence on both validity and reliability (Table 3 ). The most information was available for the SF-36 Mental Health subscale (SF-36 MH) and the SF-36 mental component summary (MCS) including moderate evidence for good construct (internal relationships) and structural validity, respectively (Table 3, supplementary Table D) .
ECONOMIC COST
Four instruments were available (Table 3 ) but none of these had evidence for both reliability and validity.
Evidence for construct validity (external relationships) was available for the EuroQol-5 Domain 3 level (EQ 5D-3L) (moderate) and the SF-6D (derived from SF-36) and Willingness-to-pay questionnaire (both limited). Differences in utility estimates from EQ-5D versus SF-6D, score distribution, floor/ceiling effects, PASS and MCII information were reported (supplementary Table D ).
PROMs measuring domains of the COS research agenda (outer circle)
SLEEP
One study assessed VAS Sleep providing information on score interpretation (Table 3, supplementary Table   D) .
STIFFNESS
Two measurements, VAS Stiffness and the NRS Stiffness were evaluated (Table 3 ) but the evidence for measurement properties remained unknown (Table 3, supplementary Table D) .
PROMS measuring domains not included in the COS
SF-36 general health subscale (GH) and the Arthritis Impact Measurement (AIMS 2) Social Support scale were evaluated but evidence for measurement properties was not achieved (Tables 3, supplementary Table   D) . PATIENT GLOBAL (n=8) Patient global due to psoriasis NRS (1 week recall) [64] + F/C VAS (1 week recall) [49] ++ ? Patient global due to arthritis NRS (1 week recall) [64] + F/C NRS (1 day recall) [44] ? ? VAS (1 week recall) [49] ++ ? Patient global due to PsA NRS (1 week recall) [53, 64] ++ F/C VAS (1 week recall) [43, 49, 50, 63] ++ + ? MID VAS (recall NS) [45] MID, [25] ? AIMS2 PC [25, 28] ? AIMS2 Mobility [24] + AIMS2 Physical [24] + AIMS2 Dexterity [24] + AIMS2 Selfcare [24] -AIMS2 House [24] -AIMS2 Arm F. [24] + [46] ? + SLEEP (n=1) VAS sleep [43] MID STIFFNESS (n=2) NRS stiffness [44] ? ? VAS stiffness [22] ? NON-COS Domains (n=2) SF-36 GH [26, 40, 50] ? [24] ?
PASS, MCII
Empty cells reflect that the measurement property was not evaluated by any study for the given instrument. 
DISCUSSION
Core outcome measurement sets (COMS) aim to ensure the best possible evaluation of the domains in a core outcome set (COS) for a specific disease, providing comparability across study results and enhancement of evidence-based health care decisions. While previous studies have provided overviews of commonly used instruments in PsA, [76, 77] this review provides a systematic identification, characterization and evidence synthesis of measurement properties of all PROMs evaluated in PsA, which constitutes an important step in the GRAPPA-OMERACT process of developing a PsA COMS.
PROMs with at least some evidence on both reliability and validity are available for six of the eight mandatory ("inner circle") COS domains including MSK disease activity (SASPA), skin disease activity impact/HRQoL domains can be generated through spydergrams. [82] It may seem practical to use a questionnaire with multiple scales that cover several domains in one application. However, it is more important to endorse the best instrument per domain and further research must be done on the measurement properties of SF-36 subscales in PsA.
All language versions of a PROM were lumped in the main evidence synthesis of this review to achieve as much information as possible per instrument. This strategy underscores the importance of collecting sufficient evidence on cross-cultural validity prior to international application of a PROM. For instance, the German SASPA (MSK disease activity) and the Italian/Turkish VITACORA-19 (HRQoL) both have some evidence for reliability and validity but translation (and cross-cultural validation) into the most common languages (English at least) is warranted. Furthermore, the evidence for content validity of PsAQoL and construct validity of HAQ-DI was rated as conflicting in the overall synthesis mainly due to diverging results across language versions. Given the limited number and quality of the included studies, future studies of high methodological standards should clarify if such differences truly exist and if they are cross-culturally related. Several studies evaluated the measurement properties of a translated questionnaire but according to COSMIN, only studies that address measurement invariance (e.g. multiple group factor analyses or DIF)
between countries (or other groups) are considered real cross-cultural validity studies.
Few studies with sufficient methodology for assessing responsiveness were identified. Although reliability and validity were considered preconditions for potential PROMs, the COMS is being developed for clinical trials for which measuring the true amount of change in a construct during an intervention is often the primary goal. Therefore, responsiveness of promising instruments needs to be clarified in future studies.
The evidence for measurement properties of PROMs measuring skin disease activity was limited since we included only studies with at least 50% of the population comprising PsA patients (or PsA subgroup results).
This strategy may be conservative, for instance additional information on the candidate instrument PSI as well as on PSD would have been achieved by including studies of psoriasis. [83] [84] [85] [86] Nevertheless, our strategy ensures that the evidence obtained applies to patients with PsA as a whole.
Strengths of this GRAPPA-OMERACT study constitute the international collaboration including experts in PsA, measurement and systematic review technique as well as patient research partners. Adherence to the COSMIN guidelines guaranties homogeneity and transparency in the assessment of methodology and rating of measurement properties across studies. Study limitations include, as for reviews in general, that negative findings might have been underreported due to publication bias. Selection bias due to exclusion of nonEnglish full-text papers may have led to underreporting of the (cross-cultural) evidence for some instruments. However we believe this was minimized as only five studies were excluded for this reason.
This review did not include RCTs or longitudinal observational studies that only provide indirect evidence for measurement properties of instruments used for assessing the outcomes of interest. We acknowledge that great amounts of indirect evidence are available and valuable in the COMS development. However the identification, selection and evaluation strategies needed for such studies do not comply with the methodology of the current review. Further analyses are currently underway by parallel work streams evaluating the data from PROMs collected in recently conducted RCTs of interventional therapies in PsA to fully adhere to the OMERACT procedure of COMS development.
This study provides an evidence based overview of measurement properties of PROMs per COS domain.
We have highlighted the current knowledge gaps, and provided an overview of available data on score interpretation, feasibility and content for each PROM. This constitutes a relevant starting point for stakeholders to decide on the overall applicability of the PROMs, and provides opportunities to improve existing data by targeted research strategies. [6, 10] This is indeed warranted as several of the PROMs with elusive measurement properties are widely used in PsA trials and clinics today. [77] Some COS domains may be more appropriately assessed by non-PROM instruments such as biomarkers and clinical assessments, and parallel work streams within GRAPPA-OMERACT are collecting psychometric evidence for the use of such tools in PsA. These research initiatives will in addition to the psychometric evidence for PsA PROMs presented in this review inform the consecutive stages of developing a COMS for PsA.
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